|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer显示文摘First-generation epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs), including gefitinib and erlotinib, have proven to be highly effective agents for advanced non-small cell lung cancer(NSCLC) in patients harboring an activating EGFR mutation such as the exon 19 deletion mutation and L858 R. Although those reversible small molecular targeted agents provide a significant response and survival benefit, all responders eventually acquire resistance. Secondgeneration EGFR-targeting agents, such as irreversible EGFR/HER2 tyrosine kinase inhibitors and pan-HER TKIs, may improve survival further and be useful for patients who acquired resistance to first-generation EGFR-TKIs. This review discusses novel therapeutic strategies for EGFR-mutated advanced NSCLC using first- and second-generation EGFR-TKIs. | Kazuhiro Asami Shinji Atagi | 2014 | World Journal of Clinical Oncology2014，5，4： | 5 |
| 2 | High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients显示文摘 | Atagi S Kawahara M | 1999 | AJR1999，173，6： | 1 |
| 3 | Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta显示文摘 | Pigino G Morfini G Atagi Y | 2009 | Proc Natl Acad Sci U S A2009，106，14： | 1 |
| 4 | Pulmonary hyalinizing granuloma with Castleman's disease显示文摘 | Atagi S Sakatani M Akira M | 1994 | Intern Med1994，33，11： | 1 |
| 5 | Specific induction of metallothionein synthesis by mitochondrial oxidative stress显示文摘 | Kondoh M Inoue Y Atagi S | 2001 | Life Sciences2001，69，： | 1 |
| 6 | LUX-Lung 4 : a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefiinib, or both 显示文摘 | Katakami N Atagi S Goto K | 2013 | J Clin Oneol2013，31，27： | 1 |
| 7 | Specific induction metallothinonein synthesis by chondrial oxidative stress显示文摘 | KONDON M INOUE Y ATAGI S | 2001 | Life Sci2001，69，18： | 1 |
| 8 | Dexmedetomidine sedationfor pediatric post-Fontan procedure patients显示文摘 | Tokuhira N Atagi K Shimaoka H | 2009 | Pediatr Crit CareMed2009，10，2： | 1 |
| 9 | High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients显示文摘 | Akira M Atagi S Kawahara M | 1999 | AJR1999，173，6： | 1 |
| 10 | Standard thoracil radiortheraqy with or without concurrent daily low-dose camoplatin in elderly patients with locally advanced non-smell lung a phase 3 trial of The Japan Clinical Oncology Group(JCOG 9812)显示文摘 | Atagis S Kawaham M Tamum T | 2005 | Jpn J Clin Oncol2005，35，4： | 1 |
| 11 | Synthetic nerve graft containing col agen and synthetic Schwann cells inproves functional,electrophysiological,and histological parameters of peripheral nerve regeneration显示文摘 | Keeley R Atagi T Sabelman E | | 0，，05： | 1 |
| 12 | A phase II trial of afatinib ( BIBW 2992) in patients ( pts ) with advanced non-small cell lung cancer previously treated with erlotinib ( E) or gefitinib (G)显示文摘 | Yamamoto N Katakami N Atagi S | 2011 | J Clin Oncol2011，，： | 1 |
| 13 | LUX-Lung 4 : Aphase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treat-ment with erlotinib, gefitinib, or both 显示文摘 | Katakami N Atagi S Goto K | 2013 | J Clin Oncol2013，31，27： | 1 |
| 14 | Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations(JO25567):an open-label,randomised,multicentre,phase 2 study显示文摘 | Seto T Kato T Nishio M Goto K Atagi S Hosomi Y | 2014 | Lancet Oncol2014，15，11： | 1 |
| 15 | High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients显示文摘 | Akira M Atagi S Kawahara M | 1999 | AJR Am J Roentgenol1999，173，： | 1 |
| 16 | Standard thoracic radio- therapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced nonsmall cell lung cancer: a phase Ⅲ trial of the Japan Clinical Oncology Group (JCOG9812) 显示文摘 | Atagi S Kawahara M Tamura T | 2005 | Jpn J Clin Oncol2005，35，： | 1 |
| 17 | Lux-Lung 4:a phase Ⅱ tri-al of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib,gefitinib,or both显示文摘 | Katakami N Atagi S Goto K | 2013 | J ClinOncol2013，31，27： | 1 |
| 18 | High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 pa- tients显示文摘 | Akira M Atagi S Kawahara M | 1999 | AJR1999，173，6： | 1 |
| 19 | Specific induction of metallothionein synthesis by mitochondrial oxidative stress显示文摘 | Kondoh M Inoue Y Atagi S | 2001 | Life Sci2001，69，： | 1 |
| 20 | A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage Ⅲ non-small cell lung cancer显示文摘 | Atagi S Kawahara M Hosoe S | 2002 | Lung Cancer2002，36，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员